Loading...
Glaukos reported Q2 2023 net sales of $80.4 million, an 11% increase year-over-year, with a gross margin of approximately 75% and a non-GAAP gross margin of approximately 82%. The company raised its 2023 net sales guidance to $304 million to $308 million.
Net sales reached $80.4 million, marking an 11% increase year-over-year.
Glaucoma net sales were $61.9 million, up 10% year-over-year.
Corneal Health net sales increased by 11% to $18.5 million.
Gross margin was approximately 75%, with a non-GAAP gross margin of about 82%.
The company expects 2023 net sales to be in the range of $304 million to $308 million based on the latest foreign currency exchange rates.